澤璟製藥(688266.SH):抗腫瘤藥物獲批臨牀試驗
格隆匯7月8日丨澤璟製藥(688266.SH)公佈,公司於近日收到國家藥監局核准簽發的《臨牀試驗通知書》。
本次獲批開展甲苯磺酸多納非尼片與傑諾單抗注射液聯合治療晚期肝細胞癌(HCC)、胃癌包括胃食管交界處腺癌(GC)、腎細胞癌(RCC)、結直腸癌(CRC)等晚期實體瘤的臨牀試驗。根據《Clinical Development Success Rates 2006-2015》公佈的數據,對於抗腫瘤藥物,一般I/II期臨牀研究階段持續約2年時間,I期完成進入II期的比率約62.8%,II期完成進入III期的比率約24.6%。由於藥品的研發週期長、審批環節多、研發投入大,容易受到一些不確定性因素的影響,敬請廣大投資者謹慎決策,注意防範投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.